Compare HALO & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HALO | ALGN |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 12.7B |
| IPO Year | 2001 | 2000 |
| Metric | HALO | ALGN |
|---|---|---|
| Price | $108.28 | $160.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $78.64 | ★ $199.82 |
| AVG Volume (30 Days) | ★ 2.3M | 890.8K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.53 |
| EPS | ★ 3.11 | 3.09 |
| Revenue | $151,862,000.00 | ★ $387,126,000.00 |
| Revenue This Year | $28.24 | $5.78 |
| Revenue Next Year | $12.56 | $4.62 |
| P/E Ratio | ★ $34.78 | $52.43 |
| Revenue Growth | N/A | ★ 23.95 |
| 52 Week Low | $61.23 | $122.00 |
| 52 Week High | $108.49 | $200.44 |
| Indicator | HALO | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 77.65 | 38.64 |
| Support Level | $67.12 | $153.68 |
| Resistance Level | N/A | $180.57 |
| Average True Range (ATR) | 3.53 | 6.14 |
| MACD | 0.75 | -1.52 |
| Stochastic Oscillator | 97.08 | 11.24 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.